J&J to buy Actelion for $30 billion


Swiss biotech company Actelion said on Thursday it had agreed to be purchased by Johnson & Johnson in a $30 billion deal.

Continue Reading Below

The all-cash offer, to acquire all of the outstanding shares of Actelion for $280 per share, payable in U.S. dollars, was unanimously approved by the Boards of Directors of both companies, Actelion and Johnson & Johnson said in a joint statement.

(Reporting by John Revill)